Authors Posts by Joshua Rodriguez

Joshua Rodriguez

2998 POSTS 445 COMMENTS
Hey everyone, I'm Joshua Rodriguez. I'm the founder of CNA Finance as well as several other sites. If you'd like to connect with me, follow me on or Twitter! I'd love to see ya there. Also, if you're looking for top quality content for your blog, news outlet, or any other website for that matter, please reach out to me at Info@CNAFin.com! Legal Disclaimer - CNA Finance is NOT an investment advisor. All investment decisions should be well thought out and made with the help of a an investment advisor. For our full legal disclaimer, please scroll to the bottom right of this page.

ibio IBIO Stock News

iBio Inc (NYSEMKT: IBIO)

iBio had an incredible day in the market yesterday. However, today that hasn’t been the case so far. Unfortunately, the stock started out on a down note and has struggled to reach the green line since. However, the bulls aren’t concerned about today’s movement as they know that gains aren’t far off. Today, we’ll talk about what caused the stock to climb yesterday, what we’re seeing today, and what we can expect to see moving forward. So, let’s get right to it…

Why IBIO Had Such An Incredible Day Yesterday

For iBio, yesterday was all about a US patent. According to the company, they received notice yesterday that their application for a monoclonal antibody was approved by the US patent office for issuance on August 26th. This is incredible news as the company works to treat influenza invections through the use of monoclonal antibodies that react to a specific protien that’s vital for the replication of the viral cells. In a release yesterday, Wayne P. Fitzmaurice, Ph.D., and vice president of iBio’s intellectual property had the following to say

The antibody covered by this patent is designed to block critical functions of the influenza virus necessary for virus replication… Current public health strategies for influenza include annual preventative vaccination and in some cases, the use of small molecule drugs for treatment of infected individuals. However, because preventive vaccination reaches only a part of the population, vaccines vary in effectiveness to prevent disease, and drug-resistant influenza strains pose increased risk, there is a global need for new, more effective therapeutic biologics that block the replication of influenza virus directly in those who become infected.”

As a result of the patent news, IBIO climbed more than 30% in the market yesterday.

What We’re Seeing Today

As mentioned above, today’s market movement is unfortunately not as strong as what we saw yesterday. As a matter of fact, the stock started with a strong downtrend; and while it has been working its way up, it is struggling to break even today. Currently (11:48), IBIO is trading at $0.81 per share after absolutely no gain at all. However, the chart looks like it may fall again. However, the bulls aren’t concerned at all. As I’ve mentioned in several previous cases that follow this type of movement, it’s important to remember that the price movements in the market happen through a series of overreactions. Therefore, the incredible news yesterday led to a bit of an overreaction; and the stock needed to fall to a more manageable rate this morning before gains could continue. This is normal market movement; and bulls know it!

What We Can Expect To See Moving Forward

Given the incredible news we got yesterday and how investors reacted to that news, I’m expecting to see more strong movement out of iBio moving forward. As a matter of fact, I received a comment on my post yesterday stating that many believe that it will reach $1.00 per share within weeks; and I’m inclined to agree with that assessment.

What Do You Think?

Where do you think IBIO is headed and why? Let us know in the comments below!

Image Credit

Biotech Stock News IBIO INO NVAX MNKD

iBio Climbs On US Patent Approval

iBio Inc (NYSEMKT: IBIO)

iBio is having an incredible day in the market today after announcing that it has received a notice from the US patent office with regard to its application for a monoclonal antibody designed to target influenza. According to the announcement, the new patent will become effective as of August 26th. As a result of the news, investors are having a field day with IBIO. Currently (1:47), the stock is trading at $0.82 per share after a gain of 34.40% so far today. Considering the reason for the gains, I don’t see this thing falling any time soon. We may see a slight correction from highs before more upward momentum, but I’m expecting to see bullish activity over all. With that said, keep your eyes on IBIO as it’s likely to generate several opportunities for strong profits in the future!

Novavax Enjoys Gains After Strong Phase 2 Trial Data

Novavax, Inc. (NASDAQ: NVAX)

Novavax is also having an incredible day in the market. Today, the company released data from its Phase 2 clinical trial looking into its RSV F-protein recombinant nanoparticle vaccine candidate and its effectiveness in adults age 60 and older. The data from the study met all primary and secondary endpoints; showing that RSV-F was well-tolerated and effective. Following the announcement of the data, NVAX saw massive gains in the market. Currently (1:59), the stock is trading at $13.80 per share after a gain of 23.28% so far today. This is another stock that considering the reason for gains today, I’m expecting to see more growth from. The reality is that investors have a reason to be excited; and while we may see a slight decline tomorrow bringing it down from highs, I think the trend is going to be upward overall in the foreseeable future. So, keep your eyes on this one as well as it’s likely to offer solid opportunities.

Inovio Is Down But Real Bulls Aren’t Worried

Inovio Pharmaceuticals Inc (NASDAQ: INO)

Inovio Pharmaceuticals is having a rough day in the market. However, if you look into the stock, it’s easy to see why INO bulls aren’t concerned in the least. Yesterday, the stock saw massive gains after the company beat earnings expectations and announced a deal with MedImmune that could yield more than $700 million as well as royalties. However, today the stock is declining. Nonetheless, in an situation like this, it’s important to remember that price movements in the market happen through a series of overreactions. So, the massive gains yesterday were the result of an overreaction to the overwhelmingly positive news. Therefore, the declines today are simply a slight correction; bringing the stock down to a more sustainable rate before growth continues. Currently (2:05), INO is trading at $7.80 per share after a loss of 4.76% so far today. Nonetheless, it may be a good time to consider getting in before gains ramp up yet again.

MannKind Corporation Working To Ward Off Bears

MannKind Corporation (NASDAQ: MNKD)

Yesterday was an incredible day for MannKind with regard to fundamentals. Not only did the company beat earnings expectations, they also announced the appointment of a new, highly qualified CMO. Another main piece of information that came yesterday was the fact that the company is getting close to regulatory approval in Europe for Afrezza. However, the bears seem to be keeping this one down; for now that is. Currently (2:08), MNKD is trading at $4.08 per share after a slight gain of 1.11% so far today. Nonetheless, I think that the bears are getting close to losing their grip and that we are likely to see big gains just around the corner. So, this is another one to keep an eye on for future opportunities.

Image Credit

MannKind MNKD Stock News

MannKind Corporation (NASDAQ: MNKD)

MannKind has had a rough time in the market recently as the shorts have been taking the stock for a ride. However, yesterday, the company released its earnings report along with tons of other good news. Nonetheless, we’re still seeing a strong tug of war in the market between the bulls and the bears. However, I think that the bears are starting to lose their grip. Today, we’ll talk about the good news that came out yesterday, what we’re seeing in the market today, and what we can expect to see moving forward. So, let’s get right to it…

MannKind Releases A Slew Of Good News

As mentioned above, yesterday, MannKind released their earnings report along with quite a bit of other good news. Here’s what we saw…

  • Earnings – First and foremost, MannKind released an earnings report that showed better than expected results. For the second quarter, the company produced a loss per share of $0.07; $0.01 ahead of analyst expectations.
  • Chief Medical Officer – We also heard about the new Chief Medical Officer that MannKind appointed yesterday. His name is Dr. Raymond Urbanski and he is definitely qualified for the job. Dr. Urbanski has 25 years of experience in the industry; in which time he held positions as the chief medical officer of Mylan as well as Metabolix. He has also held a position as the vice president of Pfizer and other strong positions in the industry. At MannKind, Dr. Urbanski will lead overall drug development activities.
  • European Approval Odds – Finally, on the earnings call, we heard more about possible approval of Afrezza in Europe. While there was no clear “yes we got approval” or “no we didn’t get approval” it was insinuated that the odds of approval are great; which coincides with the company’s decision to triple Afrezza production capabilities.

What We’re Seeing From MNKD Today

Unfortunately, the tug of war between the bulls and the bears is continuing on this one. While we did see decent gains in early morning trading, the bears have driven the stock down to nearly a break even point. Currently (1:11), MNKD is trading at $4.05 after a slight gain of 0.25% so far today.

What We Can Expect To See Moving Forward

While the bears are still holding on for dear life, it seems as though they are starting to lose their grip; and for good reason. The bottom line is that MannKind produced strong earnings, is strengthening its team, and will likely start producing strong sales figures from Afrezza relatively soon. Really, I see no reason to be bearish on this stock; that is with the exception of willful manipulation at the expense of REAL INVESTORS! With that said, we’re headed toward European approval which will likely send MNKD skyrocketing; and eventually the manipulative bears will have no choice but to find another stock to toy with.

What Do You Think

Where do you think MNKD is headed and why? Let us know in the comments below!

Image Credit

Novavax NVAX Stock news

Novavax, Inc. (NASDAQ: NVAX)

Novavax is having an incredible day in the market today after announcing top-line data from their most recent Phase 2 clinical trial. Today, we’ll take a look at the data, how the market reacted, and what we can expect from NVAX moving forward. So, let’s get right to it…

Novavax Phase 2 Trial Data

As mentioned above, Novavax announced the results of its most recent Phase 2 clinical trial this morning. The trial looked into the company’s RSV F-protein recombinant nanopartile vaccine candidate and its effectiveness in adults age 60 or older. The top-line data showed that the RSV F Vaccine was well-tolerated and ultimately fulfilled both the company’s primary and secondary objectives associated with the trial. Upon the release of the data, Dr. William Schaffner, Professor of Preventative Medicine and Infectious Diseases at Vanderbilt University Medical Center had the following to say…

It’s increasingly appreciated that RSV causes an enormous amount of illness on an annual basis, particularly in the older population. An RSV infection can predispose older adults to developing secondary pneumonia and admission to the hospital… Each year in the United States, approximately 14,000 people ages 65 or older die of RSV infections and approximately 900,000 have some sort of medical encounter with a doctor, or emergency room, or are hospitalized. Prevention remains the highest goal of medicine and those of us in preventative medicine and public health would like to prevent as many of these infections as possible.”

How The Market Reacted To The News

As we’ve come to expect any time we see positive top-line data from clinical trials, NVAX is having an incredible day in the market. Currently (12:45), the stock is trading at $13.81 per share after a gain of 23.46% as investors continue to show their excitement that revolves around the new data.

What We Can Expect To See Moving Forward

Moving forward, I’m expecting to see overwhelmingly positive news from NVAX. While we may see a slight dip from today’s highs before upward momentum continues, in my opinion, the stock is destined for growth. The reality is that the company’s RSV F vaccine is proving to be well-tolerated and effective in patients age 60 or older. Now, it’s time to move on to Phase 3; which I believe will eventually lead to FDA approval and massive growth for the company. So, keep your eyes locked on NVAX as it’s likely to present several strong opportunities for profit.

What Do You Think?

Where do you think NVAX is headed and why? Let us know in the comments below!

Image Credit

Inovio Pharmaceuticals INO Stock News

Inovio Pharmaceuticals Inc (NASDAQ: INO)

Inovio Pharmaceuticals had an incredible day in the market yesterday. Not only did the company beat earnings expectations, it announced a deal with AstraZeneca that has the potential to drive more than $700 million in revenue. However, today is a completely different story. Unfortunately, the stock is seeing declines. So below, we’ll discuss the deal with AstraZeneca, talk about why the stock is declining, and take a look at what we can expect to see moving forward. So, let’s get right to it…

Inovio Pharmaceuticals Enters Into An Agreement With MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca; and yesterday it was announced that they have entered into a definitive agreement with Inovio Pharmaceuticals that revolves around INO-3112. INO-3112 is an immunotherapy that’s designed to target cancers that have been caused by the Human Papillomavirus Infection (HPV) types 16 and 18. Under the new agreement, INO will receive an upfront payment of $27.5 million as well as the potential to earn up to $700 million more based on developmental and commercial milestones. The agreement also includes royalties paid to INO in the double digits. As a result of the news, the stock saw massive gains yesterday; climbing more than 29% in morning trading.

What We’re Seeing Today

As mentioned above, today hasn’t quite brought the good news that we saw yesterday. Currently (12:19), INO is trading at $7.91 per share after a loss of 3.44% so far. However, INO bulls really aren’t concerned about today’s declines; and for good reason. I’ve said it time and time again… One of the first things that investors need to keep in mind is that momentous price movements in the market generally happen through a series of overreactions. Therefore, yesterday, there’s no doubt that INO deserved to see gains. However, investors overreacted to the positive news; ultimately sending the stock higher than it should have gone. As a result, we’re seeing a slight correction today that’s bringing the stock down to a more manageable point before growth continues.

What We Can Expect To See Moving Forward

There’s no doubt in my mind that today’s declines are not a signal of a long term reversal. As mentioned above, what we’re seeing is a slight, short term correction. With that said, I’m expecting to see a continuation of gains that could start as early as tomorrow. All in all, Inovio has proven their ability to beat earnings expectations; and with their deal with MedImmune, there’s plenty to be excited about. So, keep a close eye on this one as it’s likely to lead to gains relatively soon.

What Do You Think?

Where do you think INO is headed and why? Let us know in the comments below!

Image Credit

IBIO Stock News

iBio Inc (NYSEMKT: IBIO)

iBio is having an incredible day in the market today after announcing that it has received notice that its application for a U.S. Patent has resulted in an issuance of the patent. Today, we’ll talk about what the patent is, how it’s affected activity in the market and what we can expect to see moving forward. So, let’s get right to it…

iBio Receives Patent

iBio announced today that it has received notice from the U.S. Patent office that its application for a monoclonal antibody has been approved and will be issued as of August 26. The antibody specified is designed to target influenza. The patent includes claims for a method of treating influenza infections through the use of monoclonal antibodies that react to the influenza neuraminidase protein; a protein that is vital for the replication and release of viral cells. Following the news, Wayne P. Fitzmaurice, Ph.D., vice president of iBio’s intellectual property had the following to say…

The antibody covered by this patent is designed to block critical functions of the influenza virus necessary for virus replication… Current public health strategies for influenza include annual preventative vaccination and in some cases, the use of small molecule drugs for treatment of infected individuals. However, because preventive vaccination reaches only a part of the population, vaccines vary in effectiveness to prevent disease, and drug-resistant influenza strains pose increased risk, there is a global need for new, more effective therapeutic biologics that block the replication of influenza virus directly in those who become infected.”

How The Market Reacted To The News

As we’ve come to expect any time we see positive news about any financial asset, iBio is climbing in the market today. Currently (11:55), the stock is trading at $0.83 per share after a gain of 34.68% so far today.

What We Can Expect To See Moving Forward

Moving forward, I’m expecting to see a continuation of positive news. After all, iBio has been granted a patent that will become effective at the end of this month. While the company is still in research and development phase, there’s plenty of reasons for investors to get excited. Nonetheless, it’s important to remember that market movement tends to happen through a series of overreactions. So, I wouldn’t be surprised to see a slight dip from current highs before gains continue.

What Do You Think?

Where do you think IBIO is headed and why? Let us know in the comments below!

Image Credit

Biotech Stock News MNKD INO AZN AMRN GILD

MannKind Beats Earnings Expectations & Excites Investors With Great News

MannKind Corporation (NASDAQ:MNKD)

MannKind is having an incredible day in the market today after releasing a slew of positive news. First and foremost, the company beat earnings expectations; producing a loss of $0.07 which was $0.01 ahead of earnings expectations. However, that wasn’t even the most positive of the news. The company also announced that it has appointed a new Chief Medical Officer by the name of Dr. Raymond Urbanski. Dr. Urbanski has extensive experience in the industry. Finally, investors found the earnings call to be incredibly impressive as the company announced several key pieces of data; one of which was that they are getting closer to Afrezza approval in Europe. All in all, the news that was released today was overwhelmingly positive; sending MNKD soaring in the market. Shortly following the earnings call, MNKD was up more than 9%. Currently (12:48), the stock is trading at $4.06 after a gain of 2.01% so far today. Considering the reason for the gains I’m expecting to see more growth as investors have plenty of reasons to be excited!

Inovio Pharmaceuticals Gains On Earnings & AstraZeneca Agreement

Inovio Pharmaceuticals Inc (NASDAQ: INO) | AstraZeneca (NYSE: AZN)

Inovio Pharmaceuticals is also having an incredible day in the market today after announcing positive earnings and more solid news. While earnings were better than expected, that wasn’t the big news for Inovio today. Instead, investors focused on a deal with MedImmune; the global biologics research and development arm of AstraZeneca. In the deal, MedImmune agreed to acquire exclusive rights to INO-3112 in exchange for a $27.5 million up front payment as well as the potential for $700 million in future payments based on developmental and commercial milestones. As a result, Inovio Pharmaceuticals is currently (12:58) trading at $8.11 per share after a gain of 24.96% so far today. Considering the reason for the gains, I’m expecting to see more and more positive news coming out of this stock. So, this is definitely one to keep an eye on.

Amarin Sees Declines Today… Real Bulls Aren’t Concerned

Amarin Corporation plc (ADR) (NASDAQ: AMRN)

Amarin had a rough start to trading this morning; starting the day off with declines. However, the bulls weren’t concerned as they watched the stock move back up to break even so far (1:00). The reality is that Amarin saw massive gains on Friday as the result of a court decision to allow the company to inform physicians of cardiovascular benefits associated with its flagship product, Vascepa. As a result, we saw double digit gains. However, as the market tends to move through overreactions, we saw a slight decline this morning; bringing it down to a more manageable point before gains started again. So far, AMRN has broken even for the day; however, even if declines start again, I don’t think that bulls will be very concerned. The bottom line is that with the new court ruling, the company will be able to promote cardiovascular benefits to physicians; ultimately leading to an increase in Vascepa sales and long term gains in the stock.

Gilead Sciences Continues Upward Movement

Gilead Sciences, Inc. (NASDAQ: GILD)

Gilead Sciences had a rough day on Thursday, followed by a relatively flat day on Friday. However, as I mentioned in my post yesterday, I wasn’t very concerned. The bottom line is that any growing stock is going to see slight dips here and there. Nonetheless, as I predicted in the post, gains started back up for GILD and are likely to continue. When it comes to Gilead Sciences, we’re talking about a company that has proven that even in the face of strong competition, they can maintain control over a tough market. Also with regulatory approval in Japan, sales of Harvoni are likely to continue to climb. With that said, we can expect to see more positive news out of Gilead Sciences moving forward. Currently (1:10), GILD is trading at $116.14 per share after a gain of 1.49% so far today.

Image Credit

Amarin Stock News

Amarin Corporation plc (ADR) (NASDAQ: AMRN)

Amarin Corporation is starting the day off on a downtrend today. However, the real bulls really aren’t concerned about today’s declines. Here’s why…

Amarin Saw Massive Gains On Friday

To understand what we’re seeing in the market today, it’s important that you know what we saw from AMRN on Friday; which proved to be an incredible day. On Friday, Amarin received a court ruling in their feud with the United States Food and Drug Administration. The court ruling gave the company the ability to inform physicians of off-label benefits of Vascepa; the company’s flagship product that has been shown in studies to offer cardiovascular benefits. As a result of the ruling, Amarin’s stock skyrocketed; ending the day with double digit gains!

What We’re Seeing From AMRN Today

Unfortunately, today is proving to be a different story. Currently (10:44), AMRN is trading at $2.32 per share after a loss of 0.43%. However, Amarin bulls really aren’t concerned about today’s declines. First and foremost, less than half a percentage point loss is not a major issue. However, aside from the size of the loss, investors aren’t concerned because what we’re seeing today is nothing more than normal market movement. The reality is that price movement in the market happens through a series of overreactions. When the positive news came out on Friday, AMRN saw massive gains. So, it’s only natural that we would see slight declines today before the gains continue. Ultimately, today’s minor declines are nothing to worry about.

What We Can Expect To See Moving Forward

Moving forward, I’m expecting to see overwhelmingly positive activity; and it all lies on the court ruling. The reality is that Vascepa has been found to have cardiovascular benefits. While those benefits aren’t approved to be included in labeling, the allowance of the company to inform physicians about these benefits is incredible. Ultimately, this will cause physicians to inform more clients of the benefits of Vascepa; leading to higher sales numbers and long run gains!

What Do You Think?

Where do you think AMRN is headed and why? Let us know in the comments below!

Image Credit

Inovio Pharmaceuticals INO Stock News

Inovio Pharmaceuticals Inc (NASDAQ: INO)

Inovio Pharmaceuticals is having an incredible day in the market today after reporting incredible financial data and announcing that it has entered into a license agreement with AstraZeneca (NYSE: AZN) for the acquisition of rights to INO-3112. Here are the details…

Inovio Pharmaceuticals Blows Earnings Expectations Out Of The Water!

As mentioned above, Inovio Pharmaceuticals presented incredible financial data; blowing earnings expectations out of the water. Here’s what we saw from the earnings report…

  • Top-Line Revenue – Top line revenue for the second quarter and first six months of 2015 both came in well above analyst expectations. For the 3 and 6 month periods, the company produced $5.3 million and $10.5 million respectively.
  • Earnings Per Share – Earnings per share came in at a loss of $0.09 for the quarter; a sharp contrast from the same period last year in which INO produced a loss of $0.18.

The Bigger Story Revolves Around INO-3112

While earnings proved to be positive, the bigger story today revolves around a deal that Inovio Pharmaceuticals made with MedImmune. MedImmune is the global biologics research and development subsidiary of AstraZenica. The announcement today outlined the fact that MedImmune and Inovio Pharmaceuticals have entered into a license agreement for the acquisition of Inovio Pharmaceuticals’ INO-3112.

According to the agreement, MedImmune will acquire exclusive rights to INO-3112; an immunotherapy that targets cancers caused by HPV types 16 and 18. The agreement is multifaceted. First and foremost, MedImmune will make an upfront payment of $27.5 million to INO. Following the upfront payment, INO will be entitled to potential future payments as INO-3112 reaches developmental and commercial milestones; which has the potential to earn INO up to $700 million in future payments. Also under the agreement, Inovio Pharmaceuticals will receive royalties that could end up in the double digits! All in all, this acquisition is a great move for both companies involved. Here are statements from key figures in both companies…

Today’s collaboration with Inovio leverages our deep internal expertise in the use of vaccines to drive antigen-specific T-cell responses. The Unique combination of our broad immuno-oncology portfolio with Inovio’s T-cell active INO-3112, which enhances cancer specific killer T-cells, has the potential to deliver real clinical benefits for patients.” – Dr. David Berman, SVP and Head of the Oncology Innovative Medicines unit at MedImmune.

Our licensing partnership with MedImmune represents and important step in executing our immuno-oncology combination strategy and advancing Inovio’s cancer vaccine R&D pipeline with a leading cancer immunotherapy company. INO-3112 is progressing, with positive interim data generated in an Inovio-initiated Phase 1 study. We appreciate MedImmune’s recognition of our ability to activate best-in-class killer T-cells in vivo and look forward to working with them on this collaboration.”

How The Market Reacted To The News

Not only did Inovio Pharmaceuticals beat earnings expectations, the deal with MedImmune is incredible news. Following positive news, we tend to expect to see gains; and that’s exactly what we’re seeing today. Currently (10:19), INO is trading at $8.40 per share after a gain of 29.40% so far today.

Image Credit

MannKind MNKD Stock News

MannKind Corporation (NASDAQ: MNKD)

As expected, MannKind reported earnings this morning. They also announced the appointment of a new chief medical officer. So today, we’ll take a look at the company’s earnings report, who they appointed as chief medical officer, and how this will affect the stock moving forward. So, let’s get right to it…

MannKind Earnings

When it comes to earnings, MannKind reported that they have beat analyst expectations. For the second quarter, analysts expected to see a loss of $0.08. However, MNKD actually reported a loss of $0.07; beating analyst expectations by one cent. However, today there is far bigger news than earnings.

MNKD Appoints New Chief Medical Officer

MannKind also released a press release this morning to announce the appointment of a new chief medical officer. The new CMO is Dr. Raymond Urbanski. As chief medical officer, Dr. Urbanski will “lead MannKind’s overall drug development activities and will be a member of the executive leadership team.” Dr. Urbanski is no stranger to the biotechnology industry. As a matter of fact, he has held CMO roles at Mylan and Metabolix. He has also held the positiion as vice president of Pfizer, as well as vice president and chief medical officer at Suntory Pharmaceuticals. Throughout the past 25 years, Dr. Urbanski has been gaining experience in the areas of oncology, rheumatology, cardiology, endocrinology, and immunology. Here’s what Hakan Edstrom, MannKind’s CEO had to say about the appointment of the new CMO…

Dr. Urbanski is a terrific addition to our team and I am very pleased to have a person of his caliber as part of the organization… Ray’s experience in drug development across multiple therapeutic areas, combined with his proven leadership capabilities, will be invaluable to us as we drive growth through our product technology platforms.”

MannKind’s Conference Call

The company has also made big announcements in the conference call following earnings. One of the biggest announcements during the earnings call was the fact that the company is getting close to approval for Afrezza in Europe. While they didn’t say they had it in the bag, it was clear that this was coming; which puts into light the reasoning behind tripling Afrezza production capability. This proved to be a big reason for excitement among investors who seem to have a majority bullish outlook according to what I’m seeing in the Stock Twits MNKD Stream.

What We’re Seeing In The Market So Far

It’s still early. Nonetheless, MNKD is seeing great growth so far this morning. Currently (9:49) the stock is trading at $4.28 per share after a gain of %7.66 so far.

What We Can Expect To See Moving Forward

If you follow my writing here or elsewhere, you know that I’ve had a bullish opinion of MNKD for quite some time now. The news today only solidifies that opinion. Moving forward, I’m expecting more growth as MNKD moves for European and Asian approval, the new CMO helps to build the company further, and Afrezza produces sales; which is likely to happen sooner than I initially expected. As with all bulls, I’m incredibly excited to see what will happen next!

What Do You Think?

Where do you think MNKD is headed and why? Let us know in the comments below!

Image Credit

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 5859
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...